A clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that psychiatrist Fred Grossman, D.O., FAPA, has been appointed to its Board of Directors.
Dr. Grossman has over two decades of expertise in clinical development and medical affairs, pharmacovigilance, and health outcomes for a wide range of pharmaceuticals, including small molecules and biologics.
Dr. Fred Grossman is put on the Board of Directors of Reunion Neuroscience.
“From Fortune 500s to early-stage pharmaceutical companies, Dr. Grossman has proven his ability to manage the entire drug lifecycle, including the approval of numerous psychiatric medications — from initial research and discovery to preclinical IND enabling studies, early- and late-phase clinical development, and postmarketing evidence generation,” said Reunion President and CEO Greg Mayes.
“As we continue to advance RE104 via the clinic, his experience on our Board will be important in accelerating the development of innovative therapy options for neglected mental health problems.”
Dr. Grossman has held senior executive leadership positions at Glenmark Pharmaceuticals, Sunovion Pharmaceuticals, Bristol Myers Squibb, Johnson & Johnson, and Eli Lilly. He was formerly the Chief Medical Officer of Empyrean Neuroscience, Mesoblast Limited, and NeuroRx Pharma.
Dr. Grossman continued, “Reunion is researching innovative patented medication candidates targeted to target particular serotonergic receptors in the brain for the possible treatment of major mental health problems.” “I see tremendous promise in these assets and look forward to collaborating with the Board to assist the management team in advancing pipeline medicines into the clinic for ultimate clearance.”
Dr. Grossman is a Fellow of the American Psychiatric Association and a Board-Certified Psychiatrist. He has written several scientific articles and held academic positions at a number of universities. He did his psychiatric residency at Hahnemann University and his fellowship in pharmacology at the National Institutes of Health (NIH).